1. Home
  2. PATH vs ERAS Comparison

PATH vs ERAS Comparison

Compare PATH & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UiPath Inc.

PATH

UiPath Inc.

SELL

Current Price

$12.39

Market Cap

7.3B

Sector

Technology

ML Signal

SELL

Logo Erasca Inc.

ERAS

Erasca Inc.

SELL

Current Price

$13.90

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PATH
ERAS
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
6.3B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
PATH
ERAS
Price
$12.39
$13.90
Analyst Decision
Hold
Buy
Analyst Count
20
9
Target Price
$15.41
★ $24.11
AVG Volume (30 Days)
★ 22.4M
4.8M
Earning Date
12-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 500.00
36.23
EPS
★ 0.11
N/A
Revenue
★ $1,610,572,000.00
N/A
Revenue This Year
$11.28
N/A
Revenue Next Year
$8.25
N/A
P/E Ratio
$119.55
★ N/A
Revenue Growth
★ 12.65
N/A
52 Week Low
$9.20
$2.75
52 Week High
$19.84
$24.28

Technical Indicators

Market Signals
Indicator
PATH
ERAS
Relative Strength Index (RSI) 39.17 43.56
Support Level $10.58 $13.18
Resistance Level $13.33 $15.71
Average True Range (ATR) 0.49 1.31
MACD -0.05 0.02
Stochastic Oscillator 8.92 18.09

Price Performance

Historical Comparison
PATH
ERAS

About PATH UiPath Inc.

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies, including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries, including claims processing, employee onboarding, invoice-to-cash, loan applications, and customer service. The company works in the Americas, Europe, the Middle East, and Africa, and Asia-Pacific, with the maximum revenue from the America.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: